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Human mesenchymal stromal 
cells exert HGF dependent 
cytoprotective effects in a human 
relevant pre-clinical model of COPD
Helen Kennelly, Bernard P. Mahon & Karen English
Bone-marrow derived mesenchymal stromal cells (MSCs) have potent immunomodulatory and tissue 
reparative properties, which may be beneficial in the treatment of inflammatory diseases such as 
COPD. This study examined the mechanisms by which human MSCs protect against elastase induced 
emphysema. Using a novel human relevant pre-clinical model of emphysema the efficacy of human 
MSC therapy and optimal cell dose were investigated. Protective effects were examined in the lung 
through histological examination. Further in vivo experiments examined the reparative abilities of 
MSCs after tissue damage was established and the role played by soluble factors secreted by MSCs. The 
mechanism of MSC action was determined in using shRNA gene knockdown. Human MSC therapy and 
MSC conditioned media exerted significant cytoprotective effects when administered early at the onset 
of the disease. These protective effects were due to significant anti-inflammatory, anti-fibrotic and anti-
apoptotic mechanisms, mediated in part through MSC production of hepatocyte growth factor (HGF). 
When MSC administration was delayed, significant protection of the lung architecture was observed 
but this was less extensive. MSC cell therapy was more effective than MSC conditioned medium in this 
emphysema model.
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disease linked to smoking and 
other respiratory insults, for which there is no cure. The prevalence of COPD is increasing and predicted to 
become the third most common cause of death worldwide by 20201. COPD is characterised by airflow obstruc-
tion linked to fibrosis of the airways and destruction of the alveolar architecture resulting in emphysema2. These 
changes follow a sustained inflammatory response with an increased immune cell infiltration and elevated levels 
of pro-inflammatory cytokines3–5. Currently the lack of effective treatments for COPD creates a requirement 
for new therapies. In developing a successful therapy for COPD, a multifactorial approach is needed, to address 
the on-going inflammation and disease process, while promoting repair of injured tissue. In this respect human 
MSCs are an attractive cellular therapy, possessing potent immunomodulatory6–8 and reparative effects9–11.
To date the most successful in vivo application of MSCs has been for acute inflammatory events including sepsis12, 
acute renal failure13, myocardial infarction14 and acute lung injury (ALI)15. However, given the wide-ranging ther-
apeutic potential of MSC, it is likely that they will be suitable for treatment of chronic diseases. An array of clinical 
trials have explored the therapeutic effects of MSCs in a range of diseases including, myocardial infarction, graft 
versus host disease and pulmonary disease16. On-going clinical trials are investigating the safety and feasibility 
and in some cases efficacy of MSCs in COPD, idiopathic pulmonary fibrosis (IPF), silicosis, bronchopulmonary 
dysplasia and acute respiratory distress syndrome17. Our work has previously demonstrated that MSCs protect 
against ovalbumin induced lung inflammation in vivo18. With proven benefits in lung disease models, this study 
sought to determine if MSCs could produce beneficial effects in a chronic disease model through promotion of 
repair as well as their established anti-inflammatory activities.
The trophic mediated effects of MSCs have become the focus of current therapeutic research. MSCs are capable 
of producing a wide range of soluble mediators that may contribute to their regenerative and protective abilities19–21; 
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identifying these will be important in effectively utilising MSCs for clinical applications. This study, sought to 
investigate both a protective and reparative role for human MSCs and identify the mechanism of action involved.
Conventional murine models for human cell therapies, face confounding effects of xenoreactivity. A human 
relevant pre-clinical model of emphysema was used to test the efficacy of human MSCs (hMSCs) as a treatment 
for COPD. The pancreatic porcine elastase (PPE) emphysema model was adapted for NOD/SCID/Il-2 receptor 
γ -chain null mice that lack an adaptive immune system, facilitating the successful administration of hMSCs. 
Utilising these immunodeficient mice ensured there was no immune response initiated to the human MSCs and 
consequently no potential reduction in their efficacy in vivo. In developing the clinical relevance of the model 
presented in this work, an MSC dose response was carried out and the timing of administration of MSC was 
examined at later timepoints with delivery after establishment of tissue damage. The use of human MSCs and 
adaptation of the emphysema model represent more accurately the clinical course of the disease and provide a 
model to assess a likely future therapy. Using specific knockdown approaches, the beneficial anti-inflammatory, 
reparative and cytoprotective effects of MSCs administered at different disease stages were characterised and a 
specific soluble effector identified.
Materials and Methods
Cell Culture. Human bone marrow MSCs were isolated as previously described22 and kindly provided by 
collaborators in REMEDI, NUI Galway. MSC and fibroblasts were grown and maintained in complete DMEM 
(cDMEM, Sigma-Aldrich, Arklow, Ireland) supplemented with 10% (v/v) FBS (BioSera, Sussex, UK) and 1% 
(v/v) Penicillin/Streptomycin (Sigma-Aldrich) and cultured at 37 °C in 5% CO2. Fibroblasts were grown and 
maintained in cDMEM, supplemented with 10% FBS, 1% penicillin/streptomycin and 1% L-glutamine in a T75 
flask at 37 °C in an incubator containing 5% CO2. Conditioned Medium (CM) was generated by culturing MSC or 
fibroblasts (1 × 105/well, 6 well plate) in cDMEM for 24 h. Cells were washed with PBS and DMEM alone added 
for 24 h. Supernatant was collected and concentrated using Amicon Ultra Centrifugal Filters (Sigma-Aldrich).
shRNA HGF Knockdown. HGF short hairpin RNA (shRNA) or non-silencing control plasmids were 
expressed in the lentiviral vector pGIPZ (Open Biosystems-Thermo, GE-Healthcare, Hatfield, UK). HGF plas-
mids were transfected into HEK293T cells with the packaging plasmid Trans-Lentiviral packaging mix using 
Mirus-TransIT-293T transfection reagent. HEK293t cells were cultured in high glucose DMEM (Sigma Aldrich) 
supplemented with 10% (v/v) FBS, 1% (v/v) penicillin/streptomycin (Invitrogen). After 24 h transfection, 30% 
FBS DMEM was added. 48 h after transfection, the supernatant containing the HGF shRNA lentivirus was col-
lected. Human MSCs (passage 2) were transduced with the viral medium for 72 h followed by positive selection 
using 4 μ g/ml Puromycin (Sigma-Aldrich).
Elastase induced mouse model of COPD. NOD.Cg-PrkdcscidIL2tmlWjl/Szj mice (NOD-SCID IL-2rgnull) 
(NSG) (Jackson Laboratories, Bar Harbour, ME,) were utilised for the elastase model. The treatment groups for 
the in vivo study included PBS only control groups, elastase only groups and elastase + MSC treatment groups. 
Mice received 30 μ g of porcine pancreatic elastase (Sigma-Aldrich) in 50 μ l PBS (or PBS only for control groups) 
by intranasal instillation per dose (total -6 doses over 2 weeks). MSCs (or PBS for control) were administered i.v. 
(intravenously) on day 0 (early administration), day 7 (mid-treatment administration) or day 14 (delayed admin-
istration). Initially a dose response was carried out using MSC at 0.1, 5, 25 or 125 × 103 cells/g. For all of the other 
experiments MSCs were administered i.v. at a dose of 25 × 103 cells/g mouse weight such that a 20 g mouse would 
receive 5 × 105 cells/mouse.
Histopathology. Lungs were harvested, formalin fixed and paraffin embedded. Tissue was sectioned and 
stained with either Mason’s Trichrome or Weigert’s Iron Hematoxylin and Eosin (Sigma-Aldrich) stain. Airway 
pathology was examined under a light microscope with at least three fields of view taken for 3 sections per mouse, 
with 5 mice per group. A blinded semi-quantitative scoring system utilising the Ashcroft scale was used to assess 
collagen deposition/fibrotic burden in the lung23. Mean linear intercept (MLI) and alveoli number were measured 
as previously described24 using image J software. The distance between the alveolar walls was measured by draw-
ing a line across each alveoli from wall to wall and recording the length for each measurement. This was carried 
out for three fields of view with three sections from each mouse lung. Alveoli number was determined by the 
number of measurements made for the MLI.
TUNEL assay. TUNEL assay was carried out using the In Situ Cell Death Detection Kit according to the man-
ufacturers instructions (Roche, Dublin, Ireland). 5 μ m tissue sections were fixed onto charged glass slides (VWR, 
Dublin, Ireland) at 50 °C overnight. Wax was removed and tissue rehydrated. Sodium Citrate antigen retrieval was 
performed. Sections were incubated at 37 °C for 1 h in humid conditions with 20 μ l label and enzyme solution. 
Tissues were counterstained with DAPI (300 nM) (Sigma-Aldrich).
Real-time PCR analysis. TriReagent (Life Technologies, Cheshire, UK) was used to isolate total RNA and 
samples were reverse transcribed to cDNA using Tetro cDNA synthesis kit (Bio- Line, London, UK). Real-time 
PCR analysis was performed using SYBR Green reagent (Sigma-Aldrich) and specific primers were utilized to determine 
gene expression. The following PCR predesigned primers were used, IL-1β F-GGATGATGATGATGATAACCTGC, 
R-CATGGAGAATATCACTTGTTGG, IL-6 F-ACAGTTGCCATGTAGACC, R-TTCTGTGACTCCAGCTTATC, 
TNFα F-GGATGAGAAGTTCCCAAATC R-TGAGAAGATGATCTGAGTGTG and GAPDH F-AGGGATT 
TGAATCACGTTTG, R- TTTACTGGCAACATCAACAG used as the house keeping gene.
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Ethical approval. All procedures involving animals were carried out by licensed personnel. Ethical approval 
for all work was received from the research ethics committee of Maynooth University. All procedures were carried 
out under an approved Department of Health animal licence.
Statistics. Statistical analysis was performed using GraphPad Prism™ software (GraphPad, San Diego, CA). 
The student’s paired t-test was used when statistical analysis was required between two experimental groups. One 
way ANOVA was used for multiple experimental group comparison. Data are presented as the ± standard error of 
the mean (SEM). P-values of p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***) were considered statistically significant.
Results
Protection by early administration of hMSC against elastase induced emphysema in a human 
relevant mouse model is dose dependent. In vitro and conventional animal models are limited substi-
tutes for examining human emphysema. A pre-clinical model of COPD was used to elucidate the effect of human 
MSC therapy on COPD in vivo. Immunocompromised NSG mice were used to facilitate the study of hMSCs as 
potential cell therapy candidates. Emphysema like changes were induced in the lung through elastase instillation 
delivered intranasally over two weeks (Fig. 1a).
In a preventative disease model, MSCs were administered at increasing doses to determine an optimal cell 
dose. Lung damage was quantified through measurement of the mean linear intercept and alveoli number. In 
comparison to healthy (PBS control) lungs, elastase caused significant damage to alveoli structures; with a break-
down in alveolar walls and decrease in alveoli number. Following hMSC administration at day 0, a protective 
effect was observed (Fig. 1) with reduced alveolar damage and reduced alveoli number loss.
Importantly, an hMSC dose as low as 0.1 × 103/g (equivalent to 1 × 105/kg) significantly decreased the mean 
linear intercept and increased the alveoli number in comparison to untreated elastase exposed mice (Fig. 1b,c). 
Figure 1. Early administration of hMSCs protects against elastase induced emphysema in a dose 
dependent manner. (a) Elastase (30 ug) was delivered intranasally (I.N) to mice to induce emphysema like 
changes in the lung. hMSCs were administered (once) intravenously 6 hours after the first elastase instillation. 
Further doses of elastase were given every 2 days over the course of two weeks, until the lungs were harvested 
for analysis on day 14. (b) Transverse tissue sections were cut and H&E stained and images were taken using 
phase contrast microscopy at a magnification of 10X. Representative images show the tissue and alveoli 
structure in control PBS lungs, elastase lungs, hMSC dose 1 (0.1 × 103 cells/g), hMSC dose 2 (5 × 103 cells/g), 
hMSC dose 3 (25 × 103 cells/g) and hMSC dose 4 (125 × 103 cells/g) treated lungs. (c) The mean linear intercept 
and alveoli number was calculated from the H&E stained lung sections for each group, with three images from 
each lung used to calculate an average using Image J software. Data presented shows the mean linear intercept 
and alveoli number for all doses. MSCs isolated from different donors were administered (once) at the optimal 
dose (25 × 103 cells/g) intravenously 6 hours after elastase on day 0. (d) Representative images show alveoli 
structure from PBS lungs, elastase lungs, MSC donor 1 lungs, MSC donor 2 lungs, MSC donor 3 lungs and 
MSC donor 4 treated lungs. (e) Data presented shows mean linear intercept and alveoli number. N = 5 mice for 
all groups. Data expressed as means ± S.E.M. Statistical analysis was carried out using one way ANOVA test. 
*p < 0.05, **p < 0.01, ***p < 0.001.
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While all hMSC doses significantly improved mean linear intercept and alveoli number, the strongest effects were 
observed with 25 × 103 cells/g and with 125 × 103 cells/g with no significant difference detected between these 
groups (Fig. 1b,c). The lower cell dose of 25 × 103 cells/g was used for all further in vivo studies.
The emphysema model was used to determine if MSC protective effects were donor specific. Elastase induced 
damage was prevented by four different hMSC donors (Fig. 1d). All MSC donors significantly reduced the mean 
linear intercept and increased alveoli number (Fig. 1e).
hMSC reduce fibrosis, apoptosis and inflammation in a humanised mouse model of emphy-
sema. Increased levels of alveolar epithelial apoptosis are a significant feature of emphysema25,26. Human MSC 
secrete a range of cytoprotective factors, with roles in protection and repair11,19,20. We have shown that soluble fac-
tors secreted into media (conditioned medium (CM)) by MSC (hMSC CM) can protect against alveolar apoptosis 
in vitro (Supp. Fig. 1). To determine if hMSC administration protected airway epithelium from apoptosis in vivo, a 
TUNEL assay was performed on tissue derived from the elastase induced emphysema model described above. As 
expected, elastase administration over the two weeks induced high levels of apoptosis when compared to control 
PBS groups (Fig. 2). hMSC treatment markedly reduced apoptosis in the lungs (Fig. 2a). To examine how hMSCs 
were exerting their protective effects in the lung, key inflammatory cytokines (IL-1β , IL-6 and TNFα) associated 
with COPD were examined by qRT-PCR. In elastase exposed lungs treated with hMSCs, there was a significant 
reduction in IL-1β and IL-6 compared to elastase only lungs (Fig. 2b) suggesting that hMSCs affect production 
of these cytokines.
The fibrotic response of lung tissue remodelling in COPD patients is also a significant contributor to the 
pathological changes associated with COPD27. To determine if hMSCs could reduce fibrosis, collagen deposition 
was assessed in the elastase model through Tri-chrome staining of lung sections using the Ashcroft scale. Alveolar 
wall thickening and collagen deposition was observed in elastase exposed airways (Fig. 2c). In contrast hMSC 
treatment of mice exposed to elastase resulted in reduced collagen deposition in the lungs (Fig. 2c) indicating a 
potential anti-fibrotic role for hMSCs when delivered intravenously on day 0.
hMSC administration during or after establishment of emphysema maintain a level of thera-
peutic efficacy. The data above show that hMSCs have in vivo therapeutic benefit early post elastase expo-
sure, however in COPD a potential therapy will have to be effective post induction of damage. To more closely 
mimic the clinical course of the disease and potential therapy in this model, administration of hMSCs was delayed 
Figure 2. hMSCs reduce fibrosis, apoptosis and inflammation in a mouse model of emphysema.  
(a) Transverse lung sections from PBS control, elastase or hMSC treated elastase mice were stained for DNA 
strand breaks by TUNEL assay, specifically with fluorescein dUTP. Lung sections were counterstained with 
DAPI and representative images are shown at 10X magnification. (b) The mRNA levels of IL-1β , IL-6 and 
TNFα were measured by qRT-PCR, changes in expression were measured relative to the house keeping gene 
GAPDH. (c) Representative images of tri-chrome stained transverse lung sections are shown for PBS, Elastase 
and Elastase + MSC (E + MSC). Histological scoring was carried out on tissue sections using the Ashcroft scale 
with three images from each lung used to calculate an average. N = 4 mice for all groups. Data expressed as 
means ± S.E.M. Statistical analysis was carried out using one way ANOVA analysis test *p < 0.05.
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to the mid-way point of the study at day 7 (Fig. 3a) ensuring that there were emphysematous changes induced in 
the lung before MSC administration.
Day 7 hMSC treatment resulted in improved lung pathology. There were marked differences in the number of 
alveoli observed and in tissue structure. The mean linear intercept was significantly decreased; with a significant 
increase in alveoli number after hMSC treatment (Fig. 3b). Notably, hMSC therapy caused a reduction in collagen 
deposition (Fig. 3c). Importantly these findings demonstrate that hMSC were able to exert cytoprotective effects 
and promote repair of previously injured tissue at a more advanced stage of the disease.
To test this effect further, a treatment model was designed to reflect the clinical course of established COPD 
and delayed therapy. This required delivering the entire course of elastase administration (6 doses of PPE) over 
two weeks without any hMSC treatment ensuring full development of emphysema (and fibrosis) in the lungs 
before hMSC delivery. hMSCs were delivered on day 12 and lungs were harvested for analysis on day 28 (Fig. 3d).
Tissue damage was assessed by H&E staining. On day 28, elastase exposed lungs displayed tissue damage and 
alveolar destruction. While hMSC mid-treatment facilitated repair in the lung (Fig. 3c), this improvement was 
not as extensive as the protective effect observed previously (Fig. 1). Delayed hMSC therapy significantly reduced 
the mean linear intercept and preserved the alveoli number in comparison to elastase exposed lungs (Fig. 3d). 
Substantial collagen deposition had developed in the elastase exposed lungs by day 28, however hMSC therapy 
administered at delayed timepoints, significantly reduced collagen deposition (Fig. 3e,f). These data suggest that 
human cell therapy might be possible in COPD despite existing lung damage.
A compaison of the effectivness of hMSC delivery at the different timepoints was made (Fig. 4). Direct compai-
son between the quantitative measurements of both the mean linear intercept (Fig. 4a) and alveoli number (Fig. 4b) 
showed the reduced effictiveness of hMSC treatment when delivered later in the course of the disease. However 
improvement in comparison to elastase only groups was still achieved with the later MSC administrations.
Figure 3. hMSC administration during or after establishment of emphysema maintain a level of 
therapeutic efficacy. Timeline of mid-treatment (a) or delayed (b) model, with MSC administered on day 7  
(a) or day 12 (b). Tissue sections were cut and H&E stained, and images taken at 10X magnification. 
Representative images show alveoli number and structure from PBS, Elastase and Elastase + hMSC- mid (Day 7) or 
delayed (Day 12) treatment lungs. Mean linear intercept and alveoli number were calculated from H&E stained 
lung sections using Image J software for (c) mid-treatment or (d) delayed treatment. Tissue was tri–chrome 
stained and images were taken at 10X magnification to assess fibrotic burden. Representative images show PBS, 
Elastase and Elastase + MSC (Day 7 or Day 12) lungs. Histological scoring was carried out on tissue sections 
using the Ashcroft scale with three images scored for each lung (e) mid-treatment and (f) delayed treatment. 
N = 4 mice for all groups and presented as mean ± S.E.M. Statistical analysis was carried out using one way 
ANOVA analysis test *p < 0.05.
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Soluble hMSC derived factors can have a protective effect in a humanised mouse model of 
emphysema. Utilising hMSC conditioned medium (CM), Supp. Fig. 1 demonstrates the in vitro cytopro-
tective effects of hMSC derived soluble factors. To examine the effect of hMSC derived trophic factors in vivo, 
the therapeutic efficacy of hMSC cells was compared to that of concentrated hMSC CM in the elastase model 
(Fig. 5a). It was important to demonstrate that any protective effects associated with CM were specific to CM 
derived from hMSC and similarly that protection associated with delivery of cells was specific to hMSC. In order 
to examine this, DMEM medium and CM from human fibroblasts was used for comparison. In addition, to 
demonstrate the specificity of the protective effects mediated by hMSC, a human fibroblast control cell population 
was also utilised. hMSC or human fibroblast CM was generated in DMEM alone for 24 h (Fig. 5b). Control groups 
receiving; fibroblast CM, fibroblast cells, or DMEM alone were also compared to mice receiving hMSCs intra-
venously. H&E staining of lungs demonstrated a cytoprotective effect for hMSC cell therapy as expected, while 
MSC CM also displayed some cytoprotection, but this protective effect was not as extensive as cell therapy. This 
difference could be due to persistence of trophic factors in the conditioned medium or might indicate that hMSC 
are acting via trophic and non-trophic mechanisms to exert their cytoprotective effects. Control groups (DMEM 
alone, fibroblast CM or fibroblast cells) demonstrated no cytoprotective effect (Fig. 5c,d).
HGF is required for hMSC therapeutic efficacy in emphysema. The study demonstrating protective 
effects of MSC-CM (Fig. 5) and the in vitro assay (Supp. Fig. 1) suggested a potential role for MSC-derived sol-
uble factors in protection against elastase induced emphysema. HGF was a likely candidate for such a role28,29. 
In order to test this hypothesis, HGF knockdown (KD) hMSCs were generated through shRNA for in vivo 
studies. Specifically this study sought to investigate the role for HGF in MSC cell mediated protection against 
elastase induced emphysema. HGF KD hMSC expressed the typical hMSC surface markers and had a signif-
icantly reduced capacity to produce HGF (Supp. Fig. 2). H&E staining demonstrated that the cytoprotective 
effect observed with hMSCs was reduced in HGF KD hMSCs. The preservation of alveolar structure observed 
with MSC treatment was decreased, with an increased destruction of alveoli walls observed. Non silencing (NS) 
control hMSCs showed similar cytoprotective abilities to hMSCs (Fig. 6a,b). The reduced cytoprotective ability 
in knockdown hMSCs indicates that sustained production of HGF may play an important role in cytoprotection 
in this model of COPD therapy.
The cytoprotective effect of hMSC might also be due to reduced apoptosis in elastase exposed lungs (Fig. 2a). 
As expected, hMSCs had an anti-apoptotic effect in the lungs, reducing the epithelial damage induced by 
elastase exposure whereas treatment with HGF KD hMSCs did not reduce the apoptosis in the lungs to the same 
extent as hMSCs or NS control hMSCs (Fig. 6c). Consequently, the anti-apoptotic effect of MSC derived HGF 
shown in vitro (Supp. Fig. 1) translated to the in vivo model, clarifying the mechanisms by which MSC support 
cytoprotection.
Discussion
MSC have emerged as novel cell therapies, due to their established immunomodulatory and anti-inflammatory 
effects, with potential to be utilised therapeutically. Given that hMSC have been shown to mediate 
anti-inflammatory effects8, reduce oxidative stress, reduce fibrosis and enhance repair30 it seems logical that 
hMSC might represent a suitable and efficacious therapy for COPD. Key pathological mechanisms of epithelial 
damage and wound formation occur in COPD, eventually leading to development of emphysema31,32. This study 
has shown that hMSC possess potent cytoprotective and reparative abilities that may limit these activities. hMSC 
CM inhibited airway epithelial cell apoptosis, while also promoting repair and proliferation via paracrine signal-
ling, supporting other studies highlighting protective effects of hMSC derived soluble mediators33,34.
Building on these beneficial properties of MSCs, an elastase induced emphysema model was used to examine 
MSC therapy. Of particular interest for the study of human therapies, this elastase model was performed in NSG 
mice, thereby creating a human relevant model of COPD, facilitating the investigation of human MSC therapy 
without the problems associated with xeno-recognition and rejection. The model of repeated elastase exposure 
was more reflective of smoking induced disease in humans and superior to single dose murine models in that 
Figure 4. Early hMSC treatment is more efficacious that delayed MSC treatment. Data from the in vivo 
studies (Figs 1 and 3) were analysed and mean linear intercept and alveoli number measured using Image J 
software. N = 4 mice for all groups and presented as mean ± S.E.M.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:38207 | DOI: 10.1038/srep38207
disease induction was cumulative. This is supported by evidence from the literature demonstrating that repeated 
administration of elastase leads to enhanced alveolar destruction and the development of pulmonary arterial 
hypertension30,35,36. A macrophage dysfunction in the NSG mice is a caveat for this study given the key role played 
by macrophages in the remodelling process associated with emphysema. Despite this defect, this model approach 
is a significant advance in that it allows comparison to mouse models (as it displays many of the features typical 
of mouse models of elastase induced emphysema) but moves to study the genuine human effector mechanisms. 
The overall goal of this research was to utilize this human relevant pre-clinical model to investigate the effect of 
human MSC on elastase induced emphysema. Although a number of studies have demonstrated the capacity for 
rodent MSCs to protect in models of elastase and cigarette-smoke induced emphysema30,37–41, few studies have 
used human MSC. The first of these studies did not examine therapeutic efficacy but focused on tracking of MSC 
in an elastase model in vivo42. The second study demonstrated efficacy of human tubal-derived MSC in combina-
tion with low level laser therapy in CS-induced COPD43. A third study demonstrated relatively modest protection 
mediated by two doses of human MSC in a CS-induced model44. Therefore, this is the first study to comprehen-
sively investigate the optimal dose, timing, efficacy of different donors and the mechanism of action involved in 
human MSC protection against emphysema in a human relevant pre-clinical model. Initially this work sought to 
establish the optimal dose for human MSC therapy in this model. While studies have compared different rodent 
MSC sources30 and delivery routes30,45 this is the first study to demonstrate a dose response. In line with hMSC 
dose selection based on hMSC/kg weight for human trials, a dose dependency study was performed based on ani-
mal weight. Comparison between the dosing study here and standard doses of MSC for patient treatment predicts 
that a lower dose might achieve efficacy based on this model. In a clinical trial for MSC treatment of COPD the 
cell dose was 100 × 106 cells per infusion with 4 doses administered per patient46. For an average patient weight of 
80 kg this represents a dose of 1.25 × 106 MSC/kg per administration and a total of 5 × 106 MSC/kg (over 4 admin-
istrations). Importantly this study demonstrated efficacy of a single administration of human MSC therapy with a 
dose as low as 0.1 × 103/g which corresponds to 1 × 105/kg. However, efficacy was significantly enhanced at higher 
doses and in a dose dependent manner with the optimal dose identified as 25 × 103/g. A recent clinical trial has 
shown that a relatively low dose of hMSC was ineffective in COPD highlighting the importance of defining the 
Figure 5. Soluble hMSC derived factors can have a protective effect in a humanised mouse model of 
emphysema. (a) Timeline (b) Generation of conditioned medium. Control DMEM, human fibroblast or 
MSC Conditioned media (CM) was administered intranasally (IN) on day 0 and compared to intravenous 
(IV) administration of MSC cells or fibroblast cells (25 × 103/g) on day 0 in elastase treated mice, timeline 
shown. (c) Transverse tissue sections were cut and H&E stained. Images were acquired using phase contrast 
microscopy at 10X magnification. Representative images show the airspace and alveolar structure in PBS, 
Elastase, Elastase + hMSC Cells, Elastase + hMSC CM, Elastase + DMEM, Elastase + Fibroblast Cells and 
Elastase + Fibroblast CM treated lungs. (d) Mean linear intercept and alveoli number were calculated from H&E 
stained lung sections using Image J software with three sections from each lung. N = 4 mice for all groups. Data 
expressed as means ± S.E.M. Statistical analysis was carried out using one way ANOVA analysis test *p < 0.05.
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optimal dose46. The data presented here supports the requirement for a dose escalation study in COPD patients to 
identify an optimal MSC dose and provides a parallel laboratory model to standardise future therapies.
Inevitably there will be some variation in donor hMSC populations due to differences in age, gender and 
health status47, with a potential significant impact on clinical outcomes. Utilising 25 × 103 cells/g this study inves-
tigated the effect (and reproducibility) of hMSC donor variation on therapeutic outcome. Notably, this work 
demonstrated comparable cytoprotective effects for different human MSC donors.
Examining this cytoprotective effect, further demonstrated an anti-inflammatory effect of MSCs, reducing 
expression of IL-1β , IL-6 and TNFα in elastase lungs. This is in agreement with other studies demonstrating a 
reduction in IL-1β and IL-6 in emphysema models48 mediated by MSC. These cytokines are present at signifi-
cantly increased levels in COPD patients with a further increase during an exacerbation49. This anti-inflammatory 
effect may be mediated by HGF inhibition of NFκ B signalling in the lungs50. Furthermore, HGF has been shown 
to downregulate IL-651 and enhance production of the natural IL-1receptor antagonist; IL-1RA52. Other studies 
have demonstrated the capacity for MSC to downregulate keratinocyte-derived chemokine (KC), TGF-β and 
COX-2-PGE-2 in rodent models of emphysema30. Although no mechanism was identified in MSC reduction 
of KC and TGF-β 30, a partial role for p38 and ERK MAPK pathways was demonstrated in MSC downregulation 
of COX-2 in a COPD model39. Apoptotic cells have been observed in lung tissue and BALF samples of COPD 
patients25,26,53, and in animal models31,54. In line with other studies30,41 an anti-apoptotic effect of MSC was iden-
tified in vitro and encouragingly, this was also detected in vivo. A marked reduction in apoptotic cells in emphy-
sematous lungs was evident after MSC treatment (day 0) and correlated with an improvement in lung pathology. 
Although more commonly associated with fibrotic lung diseases such as IPF, abnormal collagen remodelling and 
development of fibrosis is a component of COPD27,55. In contrast to the study carried out by Peron et al. showing a 
requirement for low level laser therapy in combination with human tubal derived MSC43, Antunes et al. observed 
a reduction in collagen fibre deposition mediated by mouse MSC30. Our study extends these findings demon-
strating the capacity for early, mid or delayed treatment to significantly reduce collagen deposition in the elastase 
model when bone marrow derived hMSC are used.
To better reflect the clinical course of the disease (and therefore treatment timelines) the in vivo study time-
lines were modified, delivering MSC therapy at later stages to reflect the clinical course of COPD. MSC treatment 
on day 7 (mid) or day 14 (delayed) resulted in significant cytoprotective and anti-inflammatory effects, with lung 
Figure 6. HGF is required for hMSC therapeutic efficacy in emphysema. Human HGF knockdown (KD) 
hMSCs, non-silencing control (NS) hMSCs or unmanipulated hMSCs were administered on day 0 of the 
elastase model. Lungs were harvested, formalin fixed and paraffin embedded. (a) Lung sections were H&E 
stained and images taken at 10X magnification. Representative images show PBS, Elastase, hMSC, HGF 
KD hMSC and NS control MSC groups. (b) The mean linear intercept and alveoli number were calculated 
from three H&E stained tissue sections from each mouse lung using Image J software. Data expressed as 
means ± S.E.M. Statistical analysis was carried out using one way ANOVA analysis test *p < 0.05. (c) Transverse 
lung sections were stained for DNA strand breaks by TUNEL assay, specifically with fluorescein dUTP. Lung 
sections were counterstained with DAPI. Representative images show Elastase, MSC, HGF KD MSC, and NS 
ctrl MSC. N = 4 mice for all groups.
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alveolar architecture protected from elastase damage. An important confounding consideration in this delayed 
(28 day) model is the resolution of tissue injury in mice after elastase instillation has stopped. Whilst an over-
all reduction in elastase damage compared to the previous models was observed, there was still a significant 
improvement in mean linear intercept and alveoli number as well as reduction in collagen deposition achieved 
with late MSC therapy supporting findings in other COPD models30,38,39.
It is evident that hMSC have the capacity to exert potent cytoprotective effects particularly in acute inci-
dences of inflammation and tissue damage. While they improve lung pathology at early, mid and late treatment 
timepoints, the degree to which hMSC achieve this varies. The benefits of early hMSC administration are likely 
due to the significant inflammation they encounter in injured tissue. The immunosuppressive abilities of MSC 
are enhanced by inflammatory cytokine stimulation7. Therefore it is likely that delivery of hMSC at the height of 
inflammation would improve efficacy as we have seen in other systems8.
A clinical trial of MSC for the treatment of COPD appears to confirm this enhanced effect of MSC therapy for 
acute inflammatory mediated diseases. Using allogeneic hMSCs, an early significant difference in levels of circu-
lating c-reactive protein (CRP) was observed46, however, no differences in frequencies of exacerbations or wors-
ening of disease were found. Thus, while hMSCs can reduce inflammation early after administration, the tissue 
damage can be so extensive that repair of the injured tissue is insufficient to make a difference therapeutically26. 
However, it is important to note that a dose escalation study has not yet been performed in a clinical trial for 
COPD and it may be that an optimal dose of MSC has not yet been identified for clinical efficacy. This model may 
help resolve that issue.
The in vitro work demonstrated the role of paracrine mediated effects by hMSC CM and thus CM itself was 
evaluated therapeutically in vivo demonstrating some efficacy for hMSC CM but not fibroblast CM or cells in 
comparison to non MSC CM (DMEM) treated elastase. This is in line with other studies demonstrating a pro-
tective effect mediated by MSC CM in lung injury models19,20. A protective effect for MSC-CM was also shown 
by Huh et al., however, that study administered 10 doses of MSC CM intravenously (and did not include non 
MSC CM controls)37 in comparison to the single dose administered intranasally in our study. In our study, MSC 
cellular therapy provided a significant improvement on the conditioned medium treatment. In contrast the Huh 
et al. study demonstrated comparable efficacy between a single dose of rat MSC and 10 doses of rat MSC CM37. 
The differences in these findings are likely associated with persistence of trophic factors or indicate that MSC may 
be acting through multiple (trophic and non-trophic) mechanisms in vivo.
There is a consensus that trophic factors such as VEGF and HGF may be responsible for many of the protective 
and tissue reparative effects of MSC. Utilising animal models, the beneficial effects of HGF in emphysema have 
previously been observed28,29. Importantly, while other studies have shown increased levels of VEGF or HGF 
following MSC therapy30,38,40,48, none of these studies utilised blocking or knockdown studies to verify the impor-
tance of either cytokine in hMSC cells. This is the first study to unequivocally demonstrate an important role for 
hMSC derived HGF in protection against lung injury in vivo.
MSC exerted significant anti-apoptotic effects in the elastase exposed lungs, however this effect was reduced 
with HGF knockdown MSC. Notably, the potent anti-apoptotic effect of MSC mediated against elastase induced 
emphysema has been validated both in vitro and in vivo with the importance of HGF signalling in the process 
established. This data suggests that apoptosis is a destructive component of the process of epithelial loss associated 
with emphysema and that HGF is a key anti-apoptotic factor secreted by MSC. In line with these findings, we 
and others have demonstrated an important role for HGF alone56 or in combination with PGE228 in mediating 
anti-fibrotic effects in pre-clinical models of IPF and irradiation induced lung injury. This is in direct contrast to 
recent findings demonstrating a partial role for MSC downregulation of COX-2-PGE-2 in alveolar macrophages 
in a CS-induced emphysema model. This suggests that the trophic factors or mechanism of action utilised by 
MSC may be dependent on the particular disease environment as there are important differences in the patho-
physiology of fibrotic disease and emphysema.
In conclusion we have developed a model that allows assessment of hMSC therapy for COPD. Using this and 
knockdown approaches we show that hMSCs can protect against COPD and reduce damage in part through HGF. 
Importantly, this study demonstrates the efficacy of hMSC therapy in a dose dependent manner and after the 
establishment of emphysema and supports the therapeutic potential of hMSC therapy for COPD.
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